These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 6309856)

  • 21. [Molecular mechanisms of establishment and disruption of Epstein-Barr virus latency].
    Takada K
    Tanpakushitsu Kakusan Koso; 1989 Jun; 34(7):823-34. PubMed ID: 2552500
    [No Abstract]   [Full Text] [Related]  

  • 22. A second nuclear protein is encoded by Epstein-Barr virus in latent infection.
    Hennessy K; Kieff E
    Science; 1985 Mar; 227(4691):1238-40. PubMed ID: 2983420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. II. Epstein-Barr virus studies.
    Einhorn L; Steinitz M; Yefenof E; Ernberg I; Bakacs T; Klein G
    Cell Immunol; 1978 Jan; 35(1):43-58. PubMed ID: 202404
    [No Abstract]   [Full Text] [Related]  

  • 24. Epstein-Barr virus DNA in human lymphoid cell lines: in vitro conversion.
    Andersson M; Lindahl T
    Virology; 1976 Aug; 73(1):96-105. PubMed ID: 183361
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential expression of Epstein-Barr virus (EBV) genes BBRF3, BILF1, and BMRF2 in EBV-transformed lymphoblastoid lines from ataxia-telangiectasia patients.
    Becker Y; Tabor E; Asher Y
    Leukemia; 1988 Dec; 2(12 Suppl):178S-191S. PubMed ID: 2848995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
    Klein G; Sugden B; Leibold W; Menezes J
    Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
    Cho MS; Fresen KO; zur Hausen H
    Int J Cancer; 1980 Sep; 26(3):357-63. PubMed ID: 6270006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis.
    Falk K; Ernberg I; Sakthivel R; Davis J; Christensson B; Luka J; Okano M; Grierson HL; Klein G; Purtilo DT
    Int J Cancer; 1990 Dec; 46(6):976-84. PubMed ID: 2174416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.
    Sairenji T; Hinuma Y
    Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
    Aguirre AJ; Robertson ES
    J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.
    Klein G; Lindahl T; Jondal M; Leibold W; Menézes J; Nilsson K; Sundström C
    Proc Natl Acad Sci U S A; 1974 Aug; 71(8):3283-6. PubMed ID: 4369887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of EBV and Ig/myc translocation in Burkitt lymphoma.
    Klein G
    Antibiot Chemother (1971); 1994; 46():110-6. PubMed ID: 7826031
    [No Abstract]   [Full Text] [Related]  

  • 33. Epstein-Barr viral DNA: infectivity for human placental cells.
    Miller G; Grogan E; Heston L; Robinson J; Smith D
    Science; 1981 Apr; 212(4493):452-5. PubMed ID: 6259735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line.
    Wolf J; Pawlita M; Jox A; Kohls S; Bartnitzke S; Diehl V; Bullerdiek J
    Cancer Genet Cytogenet; 1993 Jun; 67(2):90-4. PubMed ID: 8392436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Epstein-Barr virus nuclear antigen(s) in different cell lines by radioimmunoelectrophoresis.
    Sculley TB; Spelsberg TC; Pearson GR
    Intervirology; 1984; 22(4):191-200. PubMed ID: 6096291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
    Doyle MG; Crawford DH
    Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple assay method for susceptibility of human lymphocytes to Epstein-Barr virus infection.
    Takada K; Osato T
    Intervirology; 1982; 18(1-2):87-91. PubMed ID: 6288618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosome translocations, surface immunoglobulins, and Epstein-Barr virus in Japanese Burkitt's lymphoma.
    Sakurai M; Hayashi Y; Abe R; Nakazawa S
    Cancer Genet Cytogenet; 1983 Mar; 8(3):275-6. PubMed ID: 6297707
    [No Abstract]   [Full Text] [Related]  

  • 39. Epstein-Barr virus (EBV) antigenic determinants on subunits of the EBV determined nuclear antigen (EBNA).
    Hentzen D; Lenoir GM; Berthelon MC; Daillie J
    Biochem Biophys Res Commun; 1980 Sep; 96(1):425-32. PubMed ID: 6159888
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of TGF-beta on the proliferation of B cell lines and on the immortalisation of B cells by EBV.
    Altiok A; Bejarano MT; Klein E
    Curr Top Microbiol Immunol; 1990; 166():375-80. PubMed ID: 1963587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.